Basics of TGF-β and pancreatic cancer

被引:133
作者
Truty, Mark J.
Urrutia, Raul
机构
[1] Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA
[2] Mayo Clin, Clin Coll Med, Dept Surg, Rochester, MN USA
[3] Mayo Clin, Clin Coll Med, Gastrointestinal Res Unit, Rochester, MN USA
关键词
pancreatic cancer; transforming growth factor-beta; signaling system;
D O I
10.1159/000108959
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pancreatic cancer is the 4th leading cause of cancer-related death in the United States. The number of diagnoses per year equals the number of deaths per year, making it the deadliest of all malignancies. Modern advances and breakthroughs in molecular oncology have allowed researchers to gain a better understanding of the mechanisms responsible for the pathogenesis of this disease. The transforming growth factor-beta (TGF-beta) pathway is one of the signaling systems that has been identified as a major contributor. TGF-beta plays a paradoxical role as both a tumor suppressor and a tumor promoter in pancreatic cancer. The purpose of this review is to provide the practicing clinician a thorough review of this molecule and its associated signaling partners in the context of its duplicitous role and behavior in patients with pancreatic cancer. Copyright (C) 2007 S. Karger AG, Basel and IAP.
引用
收藏
页码:423 / 435
页数:13
相关论文
共 112 条
[1]   Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [J].
Aguirre, AJ ;
Bardeesy, N ;
Sinha, M ;
Lopez, L ;
Tuveson, DA ;
Horner, J ;
Redston, MS ;
DePinho, RA .
GENES & DEVELOPMENT, 2003, 17 (24) :3112-3126
[2]  
Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO
[3]  
2-8
[4]   Role of transforming growth factor-beta in growth and injury response of the pancreatic duct epithelium in vitro [J].
Alvarez, C ;
Bass, BL .
JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (02) :178-184
[5]   SARCOMA GROWTH-FACTOR FROM CONDITIONED MEDIUM OF VIRALLY TRANSFORMED-CELLS IS COMPOSED OF BOTH TYPE-ALPHA AND TYPE-BETA TRANSFORMING GROWTH-FACTORS [J].
ANZANO, MA ;
ROBERTS, AB ;
SMITH, JM ;
SPORN, MB ;
DELARCO, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (20) :6264-6268
[6]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[7]  
Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO
[8]  
2-B
[9]   Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients [J].
Bellone, G ;
Turletti, A ;
Artusio, E ;
Mareschi, K ;
Carbone, A ;
Tibaudi, D ;
Robecchi, A ;
Emanuelli, G ;
Rodeck, U .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :537-547
[10]   Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival [J].
Bellone, G ;
Smirne, C ;
Mauri, FA ;
Tonel, E ;
Carbone, A ;
Buffolino, A ;
Dughera, L ;
Robecchi, A ;
Pirisi, M ;
Emanuelli, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :684-698